We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+30.37%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$558M
AUM Growth
+$201M
Cap. Flow
+$128M
Cap. Flow %
22.94%
Top 10 Hldgs %
67.51%
Holding
90
New
30
Increased
23
Reduced
7
Closed
26

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$51.2M
2
INDP icon
Indaptus Therapeutics
INDP
+$15M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$9.52M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.24M
5
NVTA
Invitae Corporation
NVTA
+$4.06M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$12.2M
2
KITE
Kite Pharma, Inc.
KITE
+$7.78M
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$5.12M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$4.57M
5
ANAB icon
AnaptysBio
ANAB
+$3.96M

Sector Composition

Rank Sector Weight
1 Healthcare 46.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CASM
26
DELISTED
CAS Medical Systems, Inc.
CASM
$4.69M 0.84%
5,093,276
+333,125
+7% +$341K
FOLD
27
DELISTED
Amicus Therapeutics
FOLD
$4.52M 0.81%
+300,000
New +$3.97M
FXI icon
28
PUT
iShares China Large-Cap ETF
FXI
$4.35B
$4.4M 0.79%
+100,000
New +$4.29M
VIVE
29
DELISTED
VIVEVE MED INC
VIVE
$4.33M 0.78%
827
+117
+16% +$721K
SGEN
30
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
$3.81M 0.68%
+70,000
New +$3.58M
NBRV
31
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.28M 0.59%
1,600
-2,183
-58% -$5.12M
FBRX icon
32
Forte Biosciences
FBRX
$1.57B
$3.13M 0.56%
+670
New +$2.98M
QTNT
33
DELISTED
Quotient Limited Ordinary Shares
QTNT
$2.81M 0.5%
14,229
+449
+3% +$89.6K
FENC icon
34
Fennec Pharmaceuticals
FENC
$333M
$2.77M 0.5%
+250,000
New +$2.9M
ACAD icon
35
CALL
Acadia Pharmaceuticals
ACAD
$4.39B
$2.64M 0.47%
+70,000
New +$2.28M
LCI
36
PUT
DELISTED
Lannett Company, Inc.
LCI
$2.35M 0.42%
31,875
+9,475
+42% +$696K
FOLD
37
CALL
DELISTED
Amicus Therapeutics
FOLD
$2.28M 0.41%
+151,000
New +$2M
SGEN
38
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$2.18M 0.39%
+40,000
New +$2.05M
RMTI icon
39
PUT
Rockwell Medical
RMTI
$28.5M
$2.14M 0.38%
+2,273
New +$1.74M
ALXN
40
DELISTED
Alexion Pharmaceuticals
ALXN
$2.1M 0.38%
+15,000
New +$2.04M
CNC icon
41
PUT
Centene
CNC
$31.5B
$1.94M 0.35%
+40,000
New +$1.72M
NITE
42
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$1.92M 0.34%
+100,000
New +$2.16M
GOGO icon
43
PUT
Gogo Inc
GOGO
$606M
$1.59M 0.29%
135,000
+85,000
+170% +$1.08M
EVH icon
44
CALL
Evolent Health
EVH
$353M
$1.48M 0.26%
+83,000
New +$1.71M
AIMT
45
DELISTED
Aimmune Therapeutics
AIMT
$1.45M 0.26%
+58,525
New +$1.26M
CBMXW
46
DELISTED
CombiMatrix Corporation Warrant
CBMXW
$1.41M 0.25%
+564,200
New +$1.17M
AXDX
47
PUT
DELISTED
Accelerate Diagnostics
AXDX
$1.35M 0.24%
+6,000
New +$1.47M
ALIM
48
DELISTED
Alimera Sciences
ALIM
$1.31M 0.24%
64,955
– –
EVTC icon
49
PUT
Evertec
EVTC
$1.92B
$1.09M 0.2%
+68,800
New +$1.23M
PTLA
50
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.08M 0.19%
+20,000
New +$1.17M
1
2
3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2017 Portfolio in Review

As of Q3 2017, Acuta Capital Partners held 90 positions worth $558M, up 56% from $357M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Acuta Capital Partners deployed $128M of net new capital in Q3 2017, opening 30 new positions and adding to 23 existing holdings. Its largest new stake was Kadmon Holdings, Inc.: 3,333,333 shares worth $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 60% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $12.2M trimmed.

  • Acuta Capital Partners's largest Q3 2017 buy was Kadmon Holdings, Inc.: 3,333,333 shares worth $11.2M.
  • Acuta Capital Partners added most to Immunomedics Inc in Q3 2017, an estimated $51.2M increase.
  • Acuta Capital Partners's biggest Q3 2017 reduction was Ascendis Pharma A/S, cutting an estimated $12.2M.
  • Acuta Capital Partners fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $7.78M.
  • Acuta Capital Partners's ten largest holdings make up 68% of its $558M portfolio in Q3 2017.
  • Acuta Capital Partners opened 30 new positions and closed 26 in Q3 2017.
  • Acuta Capital Partners's portfolio value rose 56% quarter-over-quarter to $558M.

Based on Acuta Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.